Chardan analyst Keay Nakae initiated coverage of Coya Therapeutics with a Buy rating and $9 price target. Coya is a clinical stage company that has accumulated promising data confirming the underlying immunomodulatory properties of Tregs and their potential therapeutic benefits, the analyst tells investors in a research note. The firm believes the company is differentiated by its initial focus of using low dose IL-2 to enhance Treg function in neurodegenerative diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly